Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · IEX Real-Time Price · USD
0.525
-0.068 (-11.48%)
At close: Jul 19, 2024, 4:00 PM
0.520
-0.005 (-0.99%)
Pre-market: Jul 22, 2024, 7:30 AM EDT
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of $15.65K in the twelve months ending December 31, 2023. In the fiscal year ending June 30, 2023, Kazia Therapeutics had annual revenue of $15.86K.
Revenue (ttm)
$15.65K
Revenue Growth
-15.40%
P/S Ratio
871.14
Revenue / Employee
$1,739
Employees
9
Market Cap
13.63M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 15.86K | -2.89K | -15.40% |
Jun 30, 2022 | 18.75K | -11.43M | -99.84% |
Jun 30, 2021 | 11.45M | 10.72M | 1,464.64% |
Jun 30, 2020 | 731.72K | -370.39K | -33.61% |
Jun 30, 2019 | 1.10M | -8.61M | -88.65% |
Jun 30, 2018 | 9.71M | 2.93M | 43.28% |
Jun 30, 2017 | 6.78M | 3.75M | 123.58% |
Jun 30, 2016 | 3.03M | 840.77K | 38.39% |
Jun 30, 2015 | 2.19M | 1.79M | 441.96% |
Jun 30, 2014 | 404.14K | -1.18M | -74.45% |
Jun 30, 2013 | 1.58M | -844.31K | -34.80% |
Jun 30, 2012 | 2.43M | -63.43K | -2.55% |
Jun 30, 2011 | 2.49M | 972.97K | 64.15% |
Jun 30, 2010 | 1.52M | -509.24K | -25.13% |
Jun 30, 2009 | 2.03M | -12.27M | -85.83% |
Jun 30, 2008 | 14.30M | -2.69M | -15.82% |
Jun 30, 2007 | 16.99M | 3.44M | 25.41% |
Jun 30, 2006 | 13.54M | 95.39K | 0.71% |
Jun 30, 2005 | 13.45M | 2.03M | 17.75% |
Jun 30, 2004 | 11.42M | -4.84M | -29.77% |
Jun 30, 2003 | 16.26M | 2.58M | 18.86% |
Jun 30, 2002 | 13.68M | -5.37M | -28.17% |
Jun 30, 2001 | 19.05M | 3.04M | 18.97% |
Jun 30, 2000 | 16.01M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Flora Growth | 74.78M |
Universe Pharmaceuticals INC | 32.31M |
Psychemedics | 21.60M |
Avalo Therapeutics | 1.45M |
QT Imaging Holdings | 1.40M |
KZIA News
- 11 days ago - Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment - Benzinga
- 12 days ago - Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma - PRNewsWire
- 24 days ago - KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER - PRNewsWire
- 2 months ago - Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - PRNewsWire
- 2 months ago - KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS - PRNewsWire
- 4 months ago - Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases - PRNewsWire
- 4 months ago - Kazia announces presentation of new data at AACR Annual Meeting - PRNewsWire
- 5 months ago - Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint - PRNewsWire